-
1
-
-
33745835398
-
Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins
-
Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 2006; 86: 849-99.
-
(2006)
Physiol Rev
, vol.86
, pp. 849-899
-
-
Deeley, R.G.1
Westlake, C.2
Cole, S.P.3
-
2
-
-
33749984168
-
CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study
-
Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 2006; 6: 2706-13.
-
(2006)
Am J Transplant
, vol.6
, pp. 2706-2713
-
-
Haufroid, V.1
Wallemacq, P.2
Vankerckhove, V.3
-
3
-
-
10744222684
-
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene
-
Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481-94.
-
(2003)
Pharmacogenetics
, vol.13
, pp. 481-494
-
-
Kroetz, D.L.1
Pauli-Magnus, C.2
Hodges, L.M.3
-
4
-
-
33846558896
-
Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene
-
Kimchi-Sarfaty C, Marple AH, Shinar S, et al. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics 2007; 8: 29-39.
-
(2007)
Pharmacogenomics
, vol.8
, pp. 29-39
-
-
Kimchi-Sarfaty, C.1
Marple, A.H.2
Shinar, S.3
-
5
-
-
0034724324
-
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
-
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-8.
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, pp. 3473-3478
-
-
Hoffmeyer, S.1
Burk, O.2
von Richter, O.3
-
6
-
-
25144433260
-
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
-
Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genom 2005; 15: 693-704.
-
(2005)
Pharmacogenet Genom
, vol.15
, pp. 693-704
-
-
Wang, D.1
Johnson, A.D.2
Papp, A.C.3
Kroetz, D.L.4
Sadee, W.5
-
7
-
-
33846504706
-
A silent polymorphism in the MDR1 gene changes substrate specificity
-
Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A silent polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-8.
-
(2007)
Science
, vol.315
, pp. 525-528
-
-
Kimchi-Sarfaty, C.1
Oh, J.M.2
Kim, I.W.3
-
8
-
-
0037330517
-
Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients
-
Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89-95.
-
(2003)
Pharmacogenetics
, vol.13
, pp. 89-95
-
-
Chowbay, B.1
Cumaraswamy, S.2
Cheung, Y.B.3
Zhou, Q.4
Lee, E.J.5
-
9
-
-
4243098329
-
Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein
-
Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther 2004; 310: 1199-207.
-
(2004)
J Pharmacol Exp Ther
, vol.310
, pp. 1199-1207
-
-
Woodahl, E.L.1
Yang, Z.2
Bui, T.3
Shen, D.D.4
Ho, R.J.5
-
10
-
-
67349191460
-
MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents
-
Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ. MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol 2009; 64: 183-8.
-
(2009)
Cancer Chemother Pharmacol
, vol.64
, pp. 183-188
-
-
Woodahl, E.L.1
Crouthamel, M.H.2
Bui, T.3
Shen, D.D.4
Ho, R.J.5
-
11
-
-
23044491475
-
Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression
-
Chowbay B, Li H, David M, Cheung YB, Lee EJ. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005; 60: 159-71.
-
(2005)
Br J Clin Pharmacol
, vol.60
, pp. 159-171
-
-
Chowbay, B.1
Li, H.2
David, M.3
Cheung, Y.B.4
Lee, E.J.5
-
12
-
-
0036881149
-
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene
-
Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72: 584-94.
-
(2002)
Clin Pharmacol Ther
, vol.72
, pp. 584-594
-
-
Johne, A.1
Kopke, K.2
Gerloff, T.3
-
14
-
-
0034771497
-
MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects
-
Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18: 1400-4.
-
(2001)
Pharm Res
, vol.18
, pp. 1400-1404
-
-
Sakaeda, T.1
Nakamura, T.2
Horinouchi, M.3
-
15
-
-
12444273301
-
MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects
-
Morita Y, Sakaeda T, Horinouchi M, et al. MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res 2003; 20: 552-6.
-
(2003)
Pharm Res
, vol.20
, pp. 552-556
-
-
Morita, Y.1
Sakaeda, T.2
Horinouchi, M.3
-
16
-
-
33947157143
-
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin
-
Larsen UL, Hyldahl OL, Guldborg NC, et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest 2007; 67: 123-34.
-
(2007)
Scand J Clin Lab Invest
, vol.67
, pp. 123-134
-
-
Larsen, U.L.1
Hyldahl, O.L.2
Guldborg, N.C.3
-
17
-
-
34147130779
-
Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters
-
Comets E, Verstuyft C, Lavielle M, et al. Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. Eur J Clin Pharmacol 2007; 63: 437-49.
-
(2007)
Eur J Clin Pharmacol
, vol.63
, pp. 437-449
-
-
Comets, E.1
Verstuyft, C.2
Lavielle, M.3
-
18
-
-
40549099027
-
Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration
-
Aarnoudse AJ, Dieleman JP, Visser LE, et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genom 2008; 18: 299-305.
-
(2008)
Pharmacogenet Genom
, vol.18
, pp. 299-305
-
-
Aarnoudse, A.J.1
Dieleman, J.P.2
Visser, L.E.3
-
19
-
-
34047185923
-
Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients
-
Kurzawski M, Bartnicka L, Florczak M, Gornik W, Drozdzik M. Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacol Rep 2007; 59: 107-11.
-
(2007)
Pharmacol Rep
, vol.59
, pp. 107-111
-
-
Kurzawski, M.1
Bartnicka, L.2
Florczak, M.3
Gornik, W.4
Drozdzik, M.5
-
20
-
-
53949119164
-
Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics
-
Jiang ZP, Wang YR, Xu P, et al. Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin Pharmacol Toxicol 2008; 103: 433-44.
-
(2008)
Basic Clin Pharmacol Toxicol
, vol.103
, pp. 433-444
-
-
Jiang, Z.P.1
Wang, Y.R.2
Xu, P.3
-
21
-
-
11144358432
-
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation
-
Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422-33.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 422-433
-
-
Anglicheau, D.1
Thervet, E.2
Etienne, I.3
-
22
-
-
33750935453
-
MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients
-
Foote CJ, Greer W, Kiberd BA, et al. MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients. Transplant Proc 2006; 38: 2847-9.
-
(2006)
Transplant Proc
, vol.38
, pp. 2847-2849
-
-
Foote, C.J.1
Greer, W.2
Kiberd, B.A.3
-
23
-
-
34248996167
-
Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients
-
Foote CJ, Greer W, Kiberd B, et al. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 2007; 83: 1380-4.
-
(2007)
Transplantation
, vol.83
, pp. 1380-1384
-
-
Foote, C.J.1
Greer, W.2
Kiberd, B.3
-
24
-
-
0141765814
-
MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients
-
Mai I, Stormer E, Goldammer M, et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol 2003; 43: 1101-7.
-
(2003)
J Clin Pharmacol
, vol.43
, pp. 1101-1107
-
-
Mai, I.1
Stormer, E.2
Goldammer, M.3
-
25
-
-
0036001238
-
C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects
-
Min DI, Ellingrod VL. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2002; 24: 400-4.
-
(2002)
Ther Drug Monit
, vol.24
, pp. 400-404
-
-
Min, D.I.1
Ellingrod, V.L.2
-
26
-
-
0037906108
-
The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients
-
Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43: 555-64.
-
(2003)
J Clin Pharmacol
, vol.43
, pp. 555-564
-
-
Yates, C.R.1
Zhang, W.2
Song, P.3
-
27
-
-
0034744113
-
No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients
-
von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048-52.
-
(2001)
Clin Chem
, vol.47
, pp. 1048-1052
-
-
von Ahsen, N.1
Richter, M.2
Grupp, C.3
-
28
-
-
0041831261
-
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
-
Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54.
-
(2003)
Clin Pharmacol Ther
, vol.74
, pp. 245-254
-
-
Hesselink, D.A.1
van Schaik, R.H.2
van der Heiden, I.P.3
-
29
-
-
12144286933
-
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients
-
Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-54.
-
(2004)
Pharmacogenetics
, vol.14
, pp. 147-154
-
-
Haufroid, V.1
Mourad, M.2
van Kerckhove, V.3
-
30
-
-
33750038835
-
Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation
-
Hu YF, Qiu W, Liu ZQ, et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 2006; 33: 1093-8.
-
(2006)
Clin Exp Pharmacol Physiol
, vol.33
, pp. 1093-1098
-
-
Hu, Y.F.1
Qiu, W.2
Liu, Z.Q.3
-
31
-
-
40549132901
-
Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients
-
Crettol S, Venetz JP, Fontana M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genom 2008; 18: 307-15.
-
(2008)
Pharmacogenet Genom
, vol.18
, pp. 307-315
-
-
Crettol, S.1
Venetz, J.P.2
Fontana, M.3
-
32
-
-
21444449731
-
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation
-
Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501-11.
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 1501-1511
-
-
Hauser, I.A.1
Schaeffeler, E.2
Gauer, S.3
-
33
-
-
0035071598
-
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
-
Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91.
-
(2001)
Nat Genet
, vol.27
, pp. 383-391
-
-
Kuehl, P.1
Zhang, J.2
Lin, Y.3
-
34
-
-
21444438304
-
The pharmaco-genetics of calcineurin inhibitors: One step closer toward individualized immunosuppression?
-
Hesselink DA, van Gelder T, van Schaik RH. The pharmaco-genetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 2005; 6: 323-37.
-
(2005)
Pharmacogenomics
, vol.6
, pp. 323-337
-
-
Hesselink, D.A.1
van Gelder, T.2
van Schaik, R.H.3
-
35
-
-
7044272257
-
Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients
-
Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182-7.
-
(2004)
Transplantation
, vol.78
, pp. 1182-1187
-
-
Tsuchiya, N.1
Satoh, S.2
Tada, H.3
-
36
-
-
25144457116
-
Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation
-
Zhang X, Liu ZH, Zheng JM, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant 2005; 19: 638-43.
-
(2005)
Clin Transplant
, vol.19
, pp. 638-643
-
-
Zhang, X.1
Liu, Z.H.2
Zheng, J.M.3
-
37
-
-
33750067383
-
The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function
-
Mourad M, Wallemacq P, De Meyer M, et al. The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med 2006; 44: 1192-8.
-
(2006)
Clin Chem Lab Med
, vol.44
, pp. 1192-1198
-
-
Mourad, M.1
Wallemacq, P.2
de Meyer, M.3
-
38
-
-
34447324148
-
Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects
-
Choi JH, Lee YJ, Jang SB, et al. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol 2007; 64: 185-91.
-
(2007)
Br J Clin Pharmacol
, vol.64
, pp. 185-191
-
-
Choi, J.H.1
Lee, Y.J.2
Jang, S.B.3
-
39
-
-
36148985704
-
CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients
-
Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711-25.
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 711-725
-
-
Kuypers, D.R.1
de Jonge, H.2
Naesens, M.3
-
40
-
-
34347354233
-
Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus
-
Li D, Zhu JY, Gao J, et al. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clin Chim Acta 2007; 383: 133-9.
-
(2007)
Clin Chim Acta
, vol.383
, pp. 133-139
-
-
Li, D.1
Zhu, J.Y.2
Gao, J.3
-
41
-
-
34447549311
-
Tacrolimus pharmacokinetics and pharmacogenetics: Influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms
-
Op den Buijsch RA, Christiaans MH, Stolk LM, et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007; 21: 427-35.
-
(2007)
Fundam Clin Pharmacol
, vol.21
, pp. 427-435
-
-
Op den Buijsch, R.A.1
Christiaans, M.H.2
Stolk, L.M.3
-
42
-
-
56049118468
-
Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients
-
Quteineh L, Verstuyft C, Furlan V, et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 2008; 103: 546-52.
-
(2008)
Basic Clin Pharmacol Toxicol
, vol.103
, pp. 546-552
-
-
Quteineh, L.1
Verstuyft, C.2
Furlan, V.3
-
43
-
-
67549139183
-
The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients
-
Provenzani A, Notarbartolo M, Labbozzetta M, et al. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann Transplant 2009; 14: 23-31.
-
(2009)
Ann Transplant
, vol.14
, pp. 23-31
-
-
Provenzani, A.1
Notarbartolo, M.2
Labbozzetta, M.3
-
44
-
-
9144253194
-
MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients
-
Mai I, Perloff ES, Bauer S, et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 2004; 58: 548-53.
-
(2004)
Br J Clin Pharmacol
, vol.58
, pp. 548-553
-
-
Mai, I.1
Perloff, E.S.2
Bauer, S.3
-
45
-
-
0037693831
-
Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms
-
Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3: 477-83.
-
(2003)
Am J Transplant
, vol.3
, pp. 477-483
-
-
Zheng, H.1
Webber, S.2
Zeevi, A.3
-
46
-
-
16844380388
-
Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes
-
Zheng H, Schuetz E, Zeevi A, et al. Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes. J Clin Pharmacol 2005; 45: 404-10.
-
(2005)
J Clin Pharmacol
, vol.45
, pp. 404-410
-
-
Zheng, H.1
Schuetz, E.2
Zeevi, A.3
-
47
-
-
33646439263
-
Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients
-
Wei-lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006; 12: 775-80.
-
(2006)
Liver Transpl
, vol.12
, pp. 775-780
-
-
Wei-Lin, W.1
Jing, J.2
Shu-Sen, Z.3
-
48
-
-
0037115210
-
Tacrolimus pharmaco-genetics: Polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement
-
Macphee IA, Fredericks S, Tai T, et al. Tacrolimus pharmaco-genetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-9.
-
(2002)
Transplantation
, vol.74
, pp. 1486-1489
-
-
Macphee, I.A.1
Fredericks, S.2
Tai, T.3
-
49
-
-
0038304548
-
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients
-
Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889-96.
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 1889-1896
-
-
Anglicheau, D.1
Verstuyft, C.2
Laurent-Puig, P.3
-
50
-
-
33745179528
-
Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients
-
Cheung CY, Op den Buijsch RA, Wong KM, et al. Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics 2006; 7: 563-74.
-
(2006)
Pharmacogenomics
, vol.7
, pp. 563-574
-
-
Cheung, C.Y.1
Op den Buijsch, R.A.2
Wong, K.M.3
-
51
-
-
33745187536
-
The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients
-
Akbas SH, Bilgen T, Keser I, et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc 2006; 38: 1290-2.
-
(2006)
Transplant Proc
, vol.38
, pp. 1290-1292
-
-
Akbas, S.H.1
Bilgen, T.2
Keser, I.3
-
52
-
-
33747085521
-
Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients
-
Roy JN, Barama A, Poirier C, Vinet B, Roger M. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genom 2006; 16: 659-65.
-
(2006)
Pharmacogenet Genom
, vol.16
, pp. 659-665
-
-
Roy, J.N.1
Barama, A.2
Poirier, C.3
Vinet, B.4
Roger, M.5
-
53
-
-
33750952260
-
Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms
-
Li D, Gui R, Li J, Huang Z, Nie X. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant Proc 2006; 38: 2850-2.
-
(2006)
Transplant Proc
, vol.38
, pp. 2850-2852
-
-
Li, D.1
Gui, R.2
Li, J.3
Huang, Z.4
Nie, X.5
-
54
-
-
20344375240
-
Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients
-
Tada H, Tsuchiya N, Satoh S, et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 2005; 37: 1730-2.
-
(2005)
Transplant Proc
, vol.37
, pp. 1730-1732
-
-
Tada, H.1
Tsuchiya, N.2
Satoh, S.3
-
55
-
-
33748710224
-
Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements
-
Fredericks S, Moreton M, Reboux S, et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 2006; 82: 705-8.
-
(2006)
Transplantation
, vol.82
, pp. 705-708
-
-
Fredericks, S.1
Moreton, M.2
Reboux, S.3
-
56
-
-
31144450792
-
Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors
-
Wang J, Zeevi A, McCurry K, et al. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors. Transpl Immunol 2006; 15: 235-40.
-
(2006)
Transpl Immunol
, vol.15
, pp. 235-240
-
-
Wang, J.1
Zeevi, A.2
McCurry, K.3
-
57
-
-
34447515202
-
Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: Correlation with histopathologic staging of rejection
-
Capron A, Lerut J, Verbaandert C, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther Drug Monit 2007; 29: 340-8.
-
(2007)
Ther Drug Monit
, vol.29
, pp. 340-348
-
-
Capron, A.1
Lerut, J.2
Verbaandert, C.3
-
58
-
-
34648857526
-
1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation
-
Elens L, Capron A, Kerckhove VV, et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genom 2007; 17: 873-83.
-
(2007)
Pharmacogenet Genom
, vol.17
, pp. 873-883
-
-
Elens, L.1
Capron, A.2
Kerckhove, V.V.3
-
59
-
-
14644393732
-
Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy
-
Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005; 5: 595-603.
-
(2005)
Am J Transplant
, vol.5
, pp. 595-603
-
-
Anglicheau, D.1
le Corre, D.2
Lechaton, S.3
-
60
-
-
27644467774
-
Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids
-
Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005; 80: 977-84.
-
(2005)
Transplantation
, vol.80
, pp. 977-984
-
-
Mourad, M.1
Mourad, G.2
Wallemacq, P.3
-
61
-
-
33846632909
-
CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
-
Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81: 228-34.
-
(2007)
Clin Pharmacol Ther
, vol.81
, pp. 228-234
-
-
Renders, L.1
Frisman, M.2
Ufer, M.3
-
62
-
-
39449086203
-
Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients
-
Miao LY, Huang CR, Hou JQ, Qian MY. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 2008; 29: 1-5.
-
(2008)
Biopharm Drug Dispos
, vol.29
, pp. 1-5
-
-
Miao, L.Y.1
Huang, C.R.2
Hou, J.Q.3
Qian, M.Y.4
-
63
-
-
0036731724
-
Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies
-
Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683-90.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3683-3690
-
-
Goh, B.C.1
Lee, S.C.2
Wang, L.Z.3
-
64
-
-
33744787363
-
Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms
-
Tran A, Jullien V, Alexandre J, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006; 79: 570-80.
-
(2006)
Clin Pharmacol Ther
, vol.79
, pp. 570-580
-
-
Tran, A.1
Jullien, V.2
Alexandre, J.3
-
65
-
-
33750340905
-
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel
-
Bosch TM, Huitema AD, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006; 12: 5786-93.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5786-5793
-
-
Bosch, T.M.1
Huitema, A.D.2
Doodeman, V.D.3
-
66
-
-
18844361872
-
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1
-
Nakajima M, Fujiki Y, Kyo S, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 2005; 45: 674-82.
-
(2005)
J Clin Pharmacol
, vol.45
, pp. 674-682
-
-
Nakajima, M.1
Fujiki, Y.2
Kyo, S.3
-
67
-
-
28144461394
-
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
-
Henningsson A, Marsh S, Loos WJ, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005; 11: 8097-104.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 8097-8104
-
-
Henningsson, A.1
Marsh, S.2
Loos, W.J.3
-
68
-
-
34547922038
-
Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers
-
Jiko M, Yano I, Sato E, et al. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol 2007; 12: 284-90.
-
(2007)
Int J Clin Oncol
, vol.12
, pp. 284-290
-
-
Jiko, M.1
Yano, I.2
Sato, E.3
-
69
-
-
4544275099
-
Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia
-
Plasschaert SL, Groninger E, Boezen M, et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 2004; 76: 220-9.
-
(2004)
Clin Pharmacol Ther
, vol.76
, pp. 220-229
-
-
Plasschaert, S.L.1
Groninger, E.2
Boezen, M.3
-
70
-
-
12144286615
-
Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan
-
Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003; 13: 741-57.
-
(2003)
Pharmacogenetics
, vol.13
, pp. 741-757
-
-
Sai, K.1
Kaniwa, N.2
Itoda, M.3
-
71
-
-
34250825286
-
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer
-
Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110: 138-47.
-
(2007)
Cancer
, vol.110
, pp. 138-147
-
-
Han, J.Y.1
Lim, H.S.2
Yoo, Y.K.3
-
72
-
-
33746741049
-
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib
-
Gardner ER, Burger H, van Schaik RH, et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006; 80: 192-201.
-
(2006)
Clin Pharmacol Ther
, vol.80
, pp. 192-201
-
-
Gardner, E.R.1
Burger, H.2
van Schaik, R.H.3
-
73
-
-
34250676807
-
Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype
-
Gurney H, Wong M, Balleine RL, et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 2007; 82: 33-40.
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 33-40
-
-
Gurney, H.1
Wong, M.2
Balleine, R.L.3
-
74
-
-
52649177063
-
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
-
Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008; 112: 2024-7.
-
(2008)
Blood
, vol.112
, pp. 2024-2027
-
-
Dulucq, S.1
Bouchet, S.2
Turcq, B.3
-
75
-
-
41349107395
-
Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients
-
Lal S, Wong ZW, Sandanaraj E, et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008; 99: 816-23.
-
(2008)
Cancer Sci
, vol.99
, pp. 816-823
-
-
Lal, S.1
Wong, Z.W.2
Sandanaraj, E.3
-
76
-
-
3142751539
-
No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment
-
Winzer R, Langmann P, Zilly M, et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res 2003; 8: 531-4.
-
(2003)
Eur J Med Res
, vol.8
, pp. 531-534
-
-
Winzer, R.1
Langmann, P.2
Zilly, M.3
-
77
-
-
33947607426
-
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV
-
Ma Q, Brazeau D, Zingman BS, et al. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 2007; 8: 227-35.
-
(2007)
Pharmacogenomics
, vol.8
, pp. 227-235
-
-
Ma, Q.1
Brazeau, D.2
Zingman, B.S.3
-
78
-
-
65549158698
-
ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy
-
Estrela RC, Ribeiro FS, Barroso PF, et al. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. Pharmacogenomics 2009; 10: 311-8.
-
(2009)
Pharmacogenomics
, vol.10
, pp. 311-318
-
-
Estrela, R.C.1
Ribeiro, F.S.2
Barroso, P.F.3
-
79
-
-
1542299795
-
Oral contraception does not alter single dose saquinavir pharmacokinetics in women
-
Frohlich M, Burhenne J, Martin-Facklam M, et al. Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol 2004; 57: 244-52.
-
(2004)
Br J Clin Pharmacol
, vol.57
, pp. 244-252
-
-
Frohlich, M.1
Burhenne, J.2
Martin-Facklam, M.3
-
80
-
-
28844459455
-
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5
-
Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther 2005; 78: 605-18.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 605-618
-
-
Mouly, S.J.1
Matheny, C.2
Paine, M.F.3
-
81
-
-
34548691243
-
The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir
-
la Porte CJ, Li Y, Beique L, et al. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. Clin Pharmacol Ther 2007; 82: 389-95.
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 389-395
-
-
la Porte, C.J.1
Li, Y.2
Beique, L.3
-
82
-
-
27944466136
-
Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy
-
Verstuyft C, Marcellin F, Morand-Joubert L, et al. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS 2005; 19: 2127-31.
-
(2005)
AIDS
, vol.19
, pp. 2127-2131
-
-
Verstuyft, C.1
Marcellin, F.2
Morand-Joubert, L.3
-
83
-
-
34548036943
-
Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients
-
Solas C, Simon N, Drogoul MP, et al. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol 2007; 64: 353-62.
-
(2007)
Br J Clin Pharmacol
, vol.64
, pp. 353-362
-
-
Solas, C.1
Simon, N.2
Drogoul, M.P.3
-
84
-
-
57049102316
-
Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children
-
Curras V, Hocht C, Mangano A, et al. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children. Pharmacology 2009; 83: 59-66.
-
(2009)
Pharmacology
, vol.83
, pp. 59-66
-
-
Curras, V.1
Hocht, C.2
Mangano, A.3
-
85
-
-
30144438738
-
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1
-
Rodriguez NS, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006; 42: 291-5.
-
(2006)
Clin Infect Dis
, vol.42
, pp. 291-295
-
-
Rodriguez, N.S.1
Barreiro, P.2
Rendon, A.3
-
86
-
-
33845495422
-
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia
-
Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21: 41-6.
-
(2007)
AIDS
, vol.21
, pp. 41-46
-
-
Rodriguez-Novoa, S.1
Martin-Carbonero, L.2
Barreiro, P.3
-
87
-
-
40549144409
-
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients
-
Hirt D, Mentre F, Tran A, et al. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. Br J Clin Pharmacol 2008; 65: 548-57.
-
(2008)
Br J Clin Pharmacol
, vol.65
, pp. 548-557
-
-
Hirt, D.1
Mentre, F.2
Tran, A.3
-
88
-
-
15944414161
-
An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children
-
Saitoh A, Singh KK, Powell CA, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005; 19: 371-80.
-
(2005)
AIDS
, vol.19
, pp. 371-380
-
-
Saitoh, A.1
Singh, K.K.2
Powell, C.A.3
-
89
-
-
23444439167
-
Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo
-
Colombo S, Soranzo N, Rotger M, et al. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics 2005; 15: 599-608.
-
(2005)
Pharmacogenet Genomics
, vol.15
, pp. 599-608
-
-
Colombo, S.1
Soranzo, N.2
Rotger, M.3
-
90
-
-
37349034567
-
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children
-
Saitoh A, Sarles E, Capparelli E, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007; 21: 2191-9.
-
(2007)
AIDS
, vol.21
, pp. 2191-2199
-
-
Saitoh, A.1
Sarles, E.2
Capparelli, E.3
-
91
-
-
65449118348
-
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population
-
Mahungu T, Smith C, Turner F, et al. Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med 2009; 10: 310-7.
-
(2009)
HIV Med
, vol.10
, pp. 310-317
-
-
Mahungu, T.1
Smith, C.2
Turner, F.3
-
92
-
-
0035997339
-
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture
-
Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19: 1038-45.
-
(2002)
Pharm Res
, vol.19
, pp. 1038-1045
-
-
Stormer, E.1
von Moltke, L.L.2
Perloff, M.D.3
Greenblatt, D.J.4
-
93
-
-
47249085145
-
MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males
-
Zhang Y, Jiang XH, Hu YQ, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. Br J Clin Pharmacol 2008; 66: 247-54.
-
(2008)
Br J Clin Pharmacol
, vol.66
, pp. 247-254
-
-
Zhang, Y.1
Jiang, X.H.2
Hu, Y.Q.3
-
94
-
-
33846561513
-
Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers
-
Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007; 51: 495-502.
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 495-502
-
-
Sansone-Parsons, A.1
Krishna, G.2
Simon, J.3
-
95
-
-
58849130987
-
CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole
-
Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009; 49: 196-204.
-
(2009)
J Clin Pharmacol
, vol.49
, pp. 196-204
-
-
Weiss, J.1
ten Hoevel, M.M.2
Burhenne, J.3
-
96
-
-
16844364773
-
Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics
-
Putnam WS, Woo JM, Huang Y, Benet LZ. Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J Clin Pharmacol 2005; 45: 411-21.
-
(2005)
J Clin Pharmacol
, vol.45
, pp. 411-421
-
-
Putnam, W.S.1
Woo, J.M.2
Huang, Y.3
Benet, L.Z.4
-
97
-
-
66949157595
-
Effect of multidrug resistance gene-1 (ABCB1) polymorphisms on the single-dose pharmaco-kinetics of cloxacillin in healthy adult Chinese men
-
Yin OQ, Tomlinson B, Chow MS. Effect of multidrug resistance gene-1 (ABCB1) polymorphisms on the single-dose pharmaco-kinetics of cloxacillin in healthy adult Chinese men. Clin Ther 2009; 31: 999-1006.
-
(2009)
Clin Ther
, vol.31
, pp. 999-1006
-
-
Yin, O.Q.1
Tomlinson, B.2
Chow, M.S.3
-
98
-
-
0035752933
-
The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels
-
Kerb R, Aynacioglu AS, Brockmoller J, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenom J 2001; 1: 204-10.
-
(2001)
Pharmacogenom J
, vol.1
, pp. 204-210
-
-
Kerb, R.1
Aynacioglu, A.S.2
Brockmoller, J.3
-
99
-
-
34447501746
-
Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: A gene polymorphism perspective study
-
Ebid AH, Ahmed MM, Mohammed SA. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit 2007; 29: 305-12.
-
(2007)
Ther Drug Monit
, vol.29
, pp. 305-312
-
-
Ebid, A.H.1
Ahmed, M.M.2
Mohammed, S.A.3
-
100
-
-
33745155394
-
ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients
-
Seo T, Ishitsu T, Ueda N, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 2006; 7: 551-61.
-
(2006)
Pharmacogenomics
, vol.7
, pp. 551-561
-
-
Seo, T.1
Ishitsu, T.2
Ueda, N.3
-
101
-
-
46949108804
-
The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy
-
Basic S, Hajnsek S, Bozina N, et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 2008; 17: 524-30.
-
(2008)
Seizure
, vol.17
, pp. 524-530
-
-
Basic, S.1
Hajnsek, S.2
Bozina, N.3
-
102
-
-
2342652255
-
Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: Lack of impact of MDR-1 genotypes
-
Yasui-Furukori N, Mihara K, Takahata T, et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 2004; 57: 569-75.
-
(2004)
Br J Clin Pharmacol
, vol.57
, pp. 569-575
-
-
Yasui-Furukori, N.1
Mihara, K.2
Takahata, T.3
-
103
-
-
33750454081
-
Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients
-
Xing Q, Gao R, Li H, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006; 7: 987-93.
-
(2006)
Pharmacogenomics
, vol.7
, pp. 987-993
-
-
Xing, Q.1
Gao, R.2
Li, H.3
-
104
-
-
55349137416
-
ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active Moiety
-
Gunes A, Spina E, Dahl ML, Scordo MG. ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active Moiety. Ther Drug Monit 2008; 30: 628-33.
-
(2008)
Ther Drug Monit
, vol.30
, pp. 628-633
-
-
Gunes, A.1
Spina, E.2
Dahl, M.L.3
Scordo, M.G.4
-
105
-
-
34548728543
-
Placental transfer of quetiapine in relation to P-glycoprotein activity
-
Rahi M, Heikkinen T, Hartter S, et al. Placental transfer of quetiapine in relation to P-glycoprotein activity. J Psychopharmacol 2007; 21: 751-6.
-
(2007)
J Psychopharmacol
, vol.21
, pp. 751-756
-
-
Rahi, M.1
Heikkinen, T.2
Hartter, S.3
-
106
-
-
68449088877
-
ABCB1 and cytochrome P450 polymorphisms: Clinical pharmacogenetics of clozapine
-
Jaquenoud SE, Knezevic B, Morena GP, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009; 29: 319-26.
-
(2009)
J Clin Psychopharmacol
, vol.29
, pp. 319-326
-
-
Jaquenoud, S.E.1
Knezevic, B.2
Morena, G.P.3
-
107
-
-
34248140167
-
Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients
-
Fukui N, Suzuki Y, Sawamura K, et al. Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit 2007; 29: 185-9.
-
(2007)
Ther Drug Monit
, vol.29
, pp. 185-189
-
-
Fukui, N.1
Suzuki, Y.2
Sawamura, K.3
-
108
-
-
58149124253
-
CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and therapeutic response
-
Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008; 30: 474-82.
-
(2008)
Ther Drug Monit
, vol.30
, pp. 474-482
-
-
Gex-Fabry, M.1
Eap, C.B.2
Oneda, B.3
-
109
-
-
56949103059
-
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study
-
Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 2008; 58: 344-7.
-
(2008)
Pharmacol Res
, vol.58
, pp. 344-347
-
-
Nikisch, G.1
Eap, C.B.2
Baumann, P.3
-
110
-
-
57049097080
-
Pharmacogenetics-guided dose modifications of antidepressants
-
Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med 2008; 28: 619-26.
-
(2008)
Clin Lab Med
, vol.28
, pp. 619-626
-
-
Seeringer, A.1
Kirchheiner, J.2
-
111
-
-
0242288066
-
No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects
-
Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz DL. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 2003; 74: 487-98.
-
(2003)
Clin Pharmacol Ther
, vol.74
, pp. 487-498
-
-
Pauli-Magnus, C.1
Feiner, J.2
Brett, C.3
Lin, E.4
Kroetz, D.L.5
-
112
-
-
1242349778
-
Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers
-
Skarke C, Jarrar M, Schmidt H, et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 2003; 13: 651-60.
-
(2003)
Pharmacogenetics
, vol.13
, pp. 651-660
-
-
Skarke, C.1
Jarrar, M.2
Schmidt, H.3
-
113
-
-
33845533592
-
ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment
-
Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80: 668-81.
-
(2006)
Clin Pharmacol Ther
, vol.80
, pp. 668-681
-
-
Crettol, S.1
Deglon, J.J.2
Besson, J.3
-
114
-
-
46349104685
-
ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence
-
Levran O, O'Hara K, Peles E, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008; 17: 2219-27.
-
(2008)
Hum Mol Genet
, vol.17
, pp. 2219-2227
-
-
Levran, O.1
O'Hara, K.2
Peles, E.3
-
115
-
-
33845528364
-
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals
-
Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006; 80: 682-90.
-
(2006)
Clin Pharmacol Ther
, vol.80
, pp. 682-690
-
-
Coller, J.K.1
Barratt, D.T.2
Dahlen, K.3
Loennechen, M.H.4
Somogyi, A.A.5
-
116
-
-
0036881077
-
The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol
-
Siegmund W, Ludwig K, Giessmann T, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72: 572-83.
-
(2002)
Clin Pharmacol Ther
, vol.72
, pp. 572-583
-
-
Siegmund, W.1
Ludwig, K.2
Giessmann, T.3
-
117
-
-
23644441623
-
MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males
-
Zhang WX, Chen GL, Zhang W, et al. MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males. Clin Chim Acta 2005; 359: 46-52.
-
(2005)
Clin Chim Acta
, vol.359
, pp. 46-52
-
-
Zhang, W.X.1
Chen, G.L.2
Zhang, W.3
-
118
-
-
47649110030
-
Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1)
-
Yasar U, Babaoglu MO, Bozkurt A. Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1). Basic Clin Pharmacol Toxicol 2008; 103: 176-9.
-
(2008)
Basic Clin Pharmacol Toxicol
, vol.103
, pp. 176-179
-
-
Yasar, U.1
Babaoglu, M.O.2
Bozkurt, A.3
-
119
-
-
58149263115
-
No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects
-
Guo X, Chen XP, Cheng ZN, et al. No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects. Clin Chem Lab Med 2009; 47: 38-43.
-
(2009)
Clin Chem Lab Med
, vol.47
, pp. 38-43
-
-
Guo, X.1
Chen, X.P.2
Cheng, Z.N.3
-
120
-
-
23444433388
-
Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans
-
Brunner M, Langer O, Sunder-Plassmann R, et al. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 2005; 78: 182-90.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 182-190
-
-
Brunner, M.1
Langer, O.2
Sunder-Plassmann, R.3
-
121
-
-
33845401618
-
Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects
-
Kim KA, Park PW, Park JY. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol 2007; 63: 53-8.
-
(2007)
Br J Clin Pharmacol
, vol.63
, pp. 53-58
-
-
Kim, K.A.1
Park, P.W.2
Park, J.Y.3
-
122
-
-
68449085764
-
No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin
-
Keskitalo JE, Kurkinen KJ, Neuvonen M, et al. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009; 68: 207-13.
-
(2009)
Br J Clin Pharmacol
, vol.68
, pp. 207-213
-
-
Keskitalo, J.E.1
Kurkinen, K.J.2
Neuvonen, M.3
-
123
-
-
3242808852
-
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
-
Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429-40.
-
(2004)
Pharmacogenetics
, vol.14
, pp. 429-440
-
-
Niemi, M.1
Schaeffeler, E.2
Lang, T.3
-
124
-
-
33646911616
-
Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes
-
Hedman M, Antikainen M, Holmberg C, et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 2006; 61: 706-15.
-
(2006)
Br J Clin Pharmacol
, vol.61
, pp. 706-715
-
-
Hedman, M.1
Antikainen, M.2
Holmberg, C.3
-
125
-
-
56449116103
-
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin
-
Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008; 84: 457-61.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 457-461
-
-
Keskitalo, J.E.1
Kurkinen, K.J.2
Neuvoneni, P.J.3
Niemi, M.4
-
126
-
-
34548103493
-
Role of OATP transporters in the disposition of drugs
-
Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787-802.
-
(2007)
Pharmacogenomics
, vol.8
, pp. 787-802
-
-
Niemi, M.1
-
128
-
-
0035999902
-
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine
-
Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53: 526-34.
-
(2002)
Br J Clin Pharmacol
, vol.53
, pp. 526-534
-
-
Drescher, S.1
Schaeffeler, E.2
Hitzl, M.3
-
129
-
-
7944236606
-
A variant 2677A allele of the MDR1 gene affects fexofenadine disposition
-
Yi SY, Hong KS, Lim HS, et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 2004; 76: 418-27.
-
(2004)
Clin Pharmacol Ther
, vol.76
, pp. 418-427
-
-
Yi, S.Y.1
Hong, K.S.2
Lim, H.S.3
-
130
-
-
33845452360
-
Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus
-
Miura M, Satoh S, Tada H, et al. Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. Int J Clin Pharmacol Ther 2006; 44: 605-13.
-
(2006)
Int J Clin Pharmacol Ther
, vol.44
, pp. 605-613
-
-
Miura, M.1
Satoh, S.2
Tada, H.3
-
131
-
-
45549093053
-
Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: A possible role of intestinal CYP3A4 expression
-
Ufer M, Dilger K, Leschhorn L, et al. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther 2008; 84: 43-6.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 43-46
-
-
Ufer, M.1
Dilger, K.2
Leschhorn, L.3
-
132
-
-
46749128110
-
Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients
-
Miura M, Satoh S, Inoue K, et al. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 2008; 73: 1052-9.
-
(2008)
Steroids
, vol.73
, pp. 1052-1059
-
-
Miura, M.1
Satoh, S.2
Inoue, K.3
-
133
-
-
0037131880
-
Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): Its impact on drug disposition
-
Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 2002; 54: 1311-31.
-
(2002)
Adv Drug Deliv Rev
, vol.54
, pp. 1311-1331
-
-
Suzuki, H.1
Sugiyama, Y.2
-
134
-
-
0043130332
-
Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells
-
Oselin K, Mrozikiewicz PM, Pahkla R, Roots I. Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. Eur J Haematol 2003; 71: 119-23.
-
(2003)
Eur J Haematol
, vol.71
, pp. 119-123
-
-
Oselin, K.1
Mrozikiewicz, P.M.2
Pahkla, R.3
Roots, I.4
-
135
-
-
33847249931
-
Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex
-
Haenisch S, Zimmermann U, Dazert E, et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenom J 2007; 7: 56-65.
-
(2007)
Pharmacogenom J
, vol.7
, pp. 56-65
-
-
Haenisch, S.1
Zimmermann, U.2
Dazert, E.3
-
136
-
-
33750346955
-
Multidrug resistance protein 2 genetic polymorphisms influence myco-phenolic acid exposure in renal allograft recipients
-
Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence myco-phenolic acid exposure in renal allograft recipients. Transplantation 2006; 82: 1074-84.
-
(2006)
Transplantation
, vol.82
, pp. 1074-1084
-
-
Naesens, M.1
Kuypers, D.R.2
Verbeke, K.3
Vanrenterghem, Y.4
-
137
-
-
36148991372
-
Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients
-
Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007; 63: 1161-9.
-
(2007)
Eur J Clin Pharmacol
, vol.63
, pp. 1161-1169
-
-
Miura, M.1
Satoh, S.2
Inoue, K.3
-
138
-
-
35348836649
-
C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation
-
Baldelli S, Merlini S, Perico N, et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 2007; 8: 1127-41.
-
(2007)
Pharmacogenomics
, vol.8
, pp. 1127-1141
-
-
Baldelli, S.1
Merlini, S.2
Perico, N.3
-
139
-
-
49949100063
-
Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers
-
Levesque E, Benoit-Biancamano MO, Delage R, Couture F, Guillemette C. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics 2008; 9: 869-79.
-
(2008)
Pharmacogenomics
, vol.9
, pp. 869-879
-
-
Levesque, E.1
Benoit-Biancamano, M.O.2
Delage, R.3
Couture, F.4
Guillemette, C.5
-
140
-
-
55549110397
-
Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients
-
Zhang WX, Chen B, Jin Z, et al. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica 2008; 38: 1422-36.
-
(2008)
Xenobiotica
, vol.38
, pp. 1422-1436
-
-
Zhang, W.X.1
Chen, B.2
Jin, Z.3
-
141
-
-
33750958330
-
High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations
-
Rau T, Erney B, Gores R, et al. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 2006; 80: 468-76.
-
(2006)
Clin Pharmacol Ther
, vol.80
, pp. 468-476
-
-
Rau, T.1
Erney, B.2
Gores, R.3
-
142
-
-
66849111193
-
Comprehensive phar-macogenetic analysis of irinotecan neutropenia and pharmaco-kinetics
-
Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive phar-macogenetic analysis of irinotecan neutropenia and pharmaco-kinetics. J Clin Oncol 2009; 27: 2604-14.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2604-2614
-
-
Innocenti, F.1
Kroetz, D.L.2
Schuetz, E.3
-
143
-
-
55549141199
-
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)
-
Fujita K, Nagashima F, Yamamoto W, et al. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol Pharm Bull 2008; 31: 2137-42.
-
(2008)
Biol Pharm Bull
, vol.31
, pp. 2137-2142
-
-
Fujita, K.1
Nagashima, F.2
Yamamoto, W.3
-
144
-
-
33846012498
-
Irinotecan-induced diarrhea: Functional significance of the polymorphic ABCC2 transporter protein
-
de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007; 81: 42-9.
-
(2007)
Clin Pharmacol Ther
, vol.81
, pp. 42-49
-
-
de Jong, F.A.1
Scott-Horton, T.J.2
Kroetz, D.L.3
-
145
-
-
33745020069
-
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes
-
Zamboni WC, Ramanathan RK, McLeod HL, et al. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest New Drugs 2006; 24: 393-401.
-
(2006)
Invest New Drugs
, vol.24
, pp. 393-401
-
-
Zamboni, W.C.1
Ramanathan, R.K.2
McLeod, H.L.3
-
146
-
-
42049090195
-
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients
-
Kiser JJ, Aquilante CL, Anderson PL, et al. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 47: 298-303.
-
(2008)
J Acquir Immune Defic Syndr
, vol.47
, pp. 298-303
-
-
Kiser, J.J.1
Aquilante, C.L.2
Anderson, P.L.3
-
147
-
-
70649088033
-
Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients
-
Elens L, Yombi JC, Lison D, et al. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics 2009; 10: 1589-97.
-
(2009)
Pharmacogenomics
, vol.10
, pp. 1589-1597
-
-
Elens, L.1
Yombi, J.C.2
Lison, D.3
-
148
-
-
34447335619
-
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants
-
Ho RH, Choi L, Lee W, et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 2007; 17: 647-56.
-
(2007)
Pharmacogenet Genomics
, vol.17
, pp. 647-656
-
-
Ho, R.H.1
Choi, L.2
Lee, W.3
-
149
-
-
33645028973
-
Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms
-
Bernsdorf A, Giessmann T, Modess C, et al. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol 2006; 61: 440-50.
-
(2006)
Br J Clin Pharmacol
, vol.61
, pp. 440-450
-
-
Bernsdorf, A.1
Giessmann, T.2
Modess, C.3
-
150
-
-
33750319402
-
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics
-
Niemi M, Arnold KA, Backman JT, et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 2006; 16: 801-8.
-
(2006)
Pharmacogenet Genomics
, vol.16
, pp. 801-808
-
-
Niemi, M.1
Arnold, K.A.2
Backman, J.T.3
-
151
-
-
40549085349
-
Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol
-
Haenisch S, May K, Wegner D, et al. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics 2008; 18: 357-65.
-
(2008)
Pharmacogenet Genomics
, vol.18
, pp. 357-365
-
-
Haenisch, S.1
May, K.2
Wegner, D.3
-
152
-
-
57049170781
-
Telmisartan pharmacokinetics in Japanese renal transplant recipients
-
Miura M, Satoh S, Inoue K, et al. Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clin Chem Acta 2009; 399: 83-87.
-
(2009)
Clin Chem Acta
, vol.399
, pp. 83-87
-
-
Miura, M.1
Satoh, S.2
Inoue, K.3
-
153
-
-
0033980182
-
P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
-
Fromm M. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharm Ther 2000; 38: 69-74.
-
(2000)
Int J Clin Pharm Ther
, vol.38
, pp. 69-74
-
-
Fromm, M.1
|